These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26547483)

  • 1. A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings.
    Ke X; Eisenberg Lawrence DF; Oglesby A; Patel J; Kan H; Boggs R
    Clin Ther; 2015 Dec; 37(12):2852-63. PubMed ID: 26547483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
    von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
    Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study.
    Touma Z; Sayani A; Pineau CA; Fortin I; Matsos M; Ecker GA; Chow A; Iczkovitz S
    Rheumatol Int; 2017 Jun; 37(6):865-873. PubMed ID: 28280970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
    Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
    Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 8. Corticosteroid dosing and opioid use are high in patients with SLE and remain elevated after belimumab initiation: a retrospective claims database analysis.
    Birt JA; Wu J; Griffing K; Bello N; Princic N; Winer I; Lew CR; Costenbader KH
    Lupus Sci Med; 2020 Dec; 7(1):. PubMed ID: 33361460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
    Bell CF; Ajmera MR; Meyers J
    Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
    Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
    Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
    Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
    Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study.
    Miyazaki C; Sruamsiri R; Mahlich J; Jung W
    J Med Econ; 2020 Jul; 23(7):786-799. PubMed ID: 32149541
    [No Abstract]   [Full Text] [Related]  

  • 13. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.
    Hui-Yuen JS; Reddy A; Taylor J; Li X; Eichenfield AH; Bermudez LM; Starr AJ; Imundo LF; Buyon J; Furie RA; Kamen DL; Manzi S; Petri M; Ramsey-Goldman R; van Vollenhoven RF; Wallace DJ; Askanase A
    J Rheumatol; 2015 Dec; 42(12):2288-95. PubMed ID: 26523030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
    Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
    Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Within-trial economic analysis of flare data from the BLISS-SC trial of subcutaneous belimumab in systemic lupus erythematosus.
    Lokhandwala T; Yue B; Coutinho AD; Bell CF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33558436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
    J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study.
    Cortés-Hernández J; Marras Fernández-Cid C; Andreu Sánchez JL; Calvo Alén J; García-Aparicio AM; Díez Álvarez E; Hidalgo Bermejo FJ; Coronell C; Perna A; Ordi Ros J
    Reumatol Clin (Engl Ed); 2023; 19(6):312-318. PubMed ID: 37286267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of belimumab in patients with lupus in China: RELIABLE observational cohort study protocol.
    Fan L; Tang Z; He X; He X; Zhang Z; Juliao P
    Lupus Sci Med; 2024 Jul; 11(2):. PubMed ID: 38991834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.